Investors and Media

Press Releases

June 17, 2022

Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA)

June 9, 2022

Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference

June 2, 2022

Scholar Rock to Present at Jefferies Global Healthcare Conference 2022

May 16, 2022

Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities

April 21, 2022

Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress

March 22, 2022

Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the American Academy of Neurology 2022 Annual Meeting

March 13, 2022

Scholar Rock to Present Data from TOPAZ Ambulatory Cohort Analysis at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

March 7, 2022

Scholar Rock Reports Full Year 2021 Financial Results and Highlights Business Progress

Archived Press Releases